文献速递垂体与肾上腺疾病性腺与生殖内分泌

儿童经典型先天性肾上腺皮质增生症患者起始crinecerfont后的糖皮质激素减量:实践视角

Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文汇集11位内分泌专家意见,针对4-17岁经典型先天性肾上腺皮质增生症(CAH)患儿,在起始crinecerfont辅助治疗后如何减少糖皮质激素(GC)剂量提出推荐。减量应个体化,以雄激素浓度为指导,维持雄激素接近正常范围,实现正常生长和骨龄正常化,同时减少长期GC暴露并发症。GC应逐渐减量并频繁监测,不应低于生理性皮质醇替代所需剂量。

要点

  • GC减量应基于雄激素浓度,目标维持雄激素接近正常范围。
  • 减量需逐渐进行并频繁监测,不低于生理性皮质醇替代剂量。
  • 减量方案应个体化,结合临床目标、皮质醇需求及生活方式。

核心结论

  • crinecerfont获批使经典型CAH治疗转向以较低剂量GC主要替代皮质醇、辅助控制雄激素的新模式。

主要发现

  • GC减量策略应个体化,基于临床目标、皮质醇需求及生活方式。
  • 儿童GC减量应以雄激素浓度为指导,目标维持雄激素接近正常范围。

关键数值与推荐

  • GC剂量应逐渐减少并频繁监测,不应低于生理性皮质醇替代所需剂量。
  • 维持雄激素接近正常范围以实现正常生长和骨龄正常化,同时减少长期GC暴露并发症。

临床怎么用

  • 对4-17岁经典型CAH患儿起始crinecerfont后,依据雄激素水平逐渐减量GC并频繁监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: New and emerging non-glucocorticoid therapies for classic congenital adrenal hyperplasia (CAH) can reduce adrenocorticotropic hormone-mediated androgen production, allowing for glucocorticoid (GC) dose reductions. With the approval of crinecerfont as an adjunctive treatment to GC replacement for patients with classic CAH 4 years of age and older, expert recommendations were developed to provide guidance for GC reduction in pediatric patients after starting crinecerfont. EVIDENCE ACQUISITION: In December 2024, 11 expert endocrinologists participated in a panel to provide input on strategies and considerations when reducing GC doses after introducing crinecerfont. A smaller panel reconvened in January 2025 to review previous discussions and develop recommendations for GC dose reduction after starting crinecerfont in pediatric patients with classic CAH (4-17 years). EVIDENCE SYNTHESIS: Approaches to GC reduction should be tailored to individual clinical goals, cortisol needs, and lifestyle. In pediatric patients, GC dose reductions should be guided by androgen concentrations, with the general goal of maintaining androgens near normal range to achieve normal growth and normalize bone age maturation while also minimizing complications from long-term GC exposure. Glucocorticoid doses should be reduced gradually with frequent monitoring and should not be decreased below the dose needed for physiologic cortisol replacement. CONCLUSION: The approval of crinecerfont has initiated a shift in the treatment approach for classic CAH, in which GCs are used at lower doses predominantly for cortisol replacement. These recommendations will become increasingly relevant as treatment for these patients continues to shift toward a new paradigm of physiologic GC replacement with adjunctive control of androgens.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nokoff NJ, Fechner PY, Kim MS, et al. Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives. J Clin Endocrinol Metab. 2026. PMID: 42082437. doi:10.1210/clinem/dgag192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。